CUE RSI Strategy
Today’s Change (Nov 22, 2026)
—
A symphony is an automated trading strategy — Learn more about symphonies here
About
A simple rule-based strategy that buys volatile biotech stock CUE only after heavy recent selling, and otherwise sits in BIL, a cash-like short-term Treasury fund.
This strategy watches one stock: Cue Biopharma (CUE), a small biotech company that can move sharply on news.
Each day it checks CUE’s 14-day RSI, a simple score of how heavily the stock has been sold lately. If that score is below 30, the strategy buys CUE, assuming it may be due for a rebound. If not, it moves into BIL, a very short-term U.S. Treasury fund used like cash.
Out-of-sample, this RSI-based biotech strategy beats the S&P on risk-adjusted return: Sharpe ~0.76 vs 0.58, annualized ~40% vs ~9%, with alpha and a cash buffer in BIL. Expect higher drawdowns (up to ~50%).
1M
3M
6M
YTD
1Y
3Y
Max
Performance
Compared to selected benchmarks
| Alpha | Beta | R2 | R | |
|---|---|---|---|---|
| 0.28 | 0.14 | 0 | 0.06 |
Performance Metrics
| Cumulative Return | Annualized Return | Trailing 1M Return | Trailing 3M Return | Sharpe Ratio | |
|---|---|---|---|---|---|
| 178.06% | 12.3% | -10.3% | -9.32% | 0.7 | |
| 619.29% | 25.09% | 47.06% | 47.95% | 0.71 |
Initial Investment
$10,000.00
Final Value
$71,929.24Regulatory Fees
$50.38
Total Slippage
$379.73
Invest in this strategy
OOS Start Date
Nov 7, 2024
Trading Setting
Daily
Type
Stocks
Category
Rsi, mean reversion, single-stock biotech, tactical allocation, cash equivalent, daily rebalance
Tickers in this symphonyThis symphony trades 2 assets in total
Ticker
Type
BIL
SPDR Series Trust - State Street SPDR Bloomberg 1-3 Month T-Bill ETF
Stocks
CUE
Cue Biopharma Inc
Stocks